← Back to Clinical Trials
Recruiting NCT05922644

NCT05922644 Short-term Cervical Spinal Cord Stimulation in Patients With Disorders of Consciousness After Intracerebral Hemorrhage

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05922644
Status Recruiting
Phase
Sponsor Beijing Tiantan Hospital
Condition Coma
Study Type INTERVENTIONAL
Enrollment 344 participants
Start Date 2023-07-01
Primary Completion 2026-09-01

Trial Parameters

Condition Coma
Sponsor Beijing Tiantan Hospital
Study Type INTERVENTIONAL
Phase N/A
Enrollment 344
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2023-07-01
Completion 2026-09-01
All Conditions
Interventions
SCSConventional

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Disorders of consciousness (DOC) refers to the persistent loss of consciousness after 28 days in patients with brain injury caused by trauma, stroke, or hypoxia. It includes coma, vegetative state, and minimally conscious state. At present, there is no effective treatment for DOC. Only one RCT study of amantadine has proved that it may be effective for the treatment of DOC. In recent years, more evidence has shown that neuromodulation technology is beneficial to the recovery of DOC. Cervical spinal cord stimulation surgery is a new treatment method for patients with DOC. Electrodes are implanted in the high cervical spinal cord C2-C5. By adjusting different electrical stimulation parameters, it has a wake-promoting effect. In this study, patients were selected into the spinal cord stimulation group and the conventional treatment group according to the wishes of their families. The patients in the spinal cord stimulation group were given 21 days of cervical spinal cord stimulation treatment on the basis of conventional brain rehabilitation. Patients were followed up routinely and completed designated examinations at 12 months to determine the safety and efficacy of cervical spinal cord stimulation therapy.

Eligibility Criteria

Inclusion Criteria: * Age between 18 and 65 years old * Patients with postoperative consciousness disorders after cerebral hemorrhage for more than 28 days * CRS-R score meets the MCS diagnosis * Signed informed consent. Exclusion Criteria: * Secondary brain injury caused by arteriovenous malformation, cerebral aneurysm, cavernous hemangioma, brain tumor and carbon monoxide poisoning * History of previous epileptic seizures * Critical condition, unstable intracranial condition, risk of rebleeding * Unstable vital signs requiring mechanical ventilation * Contraindications for spinal cord surgery * Severe sympathetic overactivity syndrome.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology